A- A A+

UNAIDS. Promises to improve health outcomes for people who inject drugs remain unfulfilled as 99% do not have adequate access to harm reduction services 

New report by UNAIDS highlights the urgent need to implement a human rights and evidence-informed approach to reach people who inject drugs with essential health services. (UNAIDS, Genf, 13.03.2019)

http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190313_drugs_report

UNAIDS. HEALTH, RIGHTS AND DRUGS - HARM REDUCTION, DECRIMINALIZATION AND ZERO DISCRIMINATION FOR PEOPLE WHO USE DRUGS

(UNAIDS, 2019)

http://www.unaids.org/sites/default/files/media_asset/JC2954_UNAIDS_drugs_report_2019_en.pdf

Deutsche AIDS-Hilfe: HIV-Test

Manchmal muss man’s einfach wissen. Gerade nach einer Risikosituation ist es wichtig, Gewissheit zu haben, dass nichts passiert ist. Ein HIV-Test schafft Klarheit. 

Inhalt: Überblick zum HIV-Test - Gute Gründe für den HIV-Test - HIV-Tests im Überblick - HIV-Selbsttest - Wo auf HIV testen lassen? (DAH, 2019)

https://www.aidshilfe.de/hiv-test

HIV-Patient symptomfrei nach Knochenmarktransplantation

London – Der „Berliner Patient“ Timothy Ray Brown galt bisher als weltweiter Einzelfall, der von einer HIV-Infektion geheilt werden konnte. Einer Studie in Naturezufolge könnte es nun einen zweiten Fall in London geben (2019; doi: 10.1038/s41586-019-1027-4). (aerzteblatt.de, 05.03.2019)

https://www.aerzteblatt.de/nachrichten/101418/HIV-Patient-symptomfrei-nach-Knochenmarktransplantation

HIV crisis in the Philippines: urgent actions needed

Gangcuangco, Louie Mar A

The Lancet Public Health , Volume 4 , Issue 2 , e84 

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30265-2/fulltext

Addressing the HIV crisis in the Philippines

Marston, Jez Lim et al.

The Lancet Public Health , Volume 4 , Issue 3 , e126

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30024-6/fulltext

International AIDS Society. Getting to the Heart of Stigma

“THE PERSISTENCE OF STIGMA IN THE CONTEXT OF HIV ALSO CAUSES IMMENSE HUMAN HARDSHIP AND DIMINISHES US AS A GLOBAL COMMUNITY.”

IAS – International AIDS Society, Annual Letter, Februar 2019-03-02

https://www.iasociety.org/Who-we-are/About-the-IAS/Annual-Letter-2019

A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?

Leung J, Peacock A, Colledge S, Grebely J, Cunningham EB, Hickman M, Vickerman P, Stone J, Trickey A, Dumchev K, Lynskey M, Hines L, Griffiths P, Mattick RP, Degenhardt L, Larney S.

J Infect Dis. 2019 Feb 6. doi: 10.1093/infdis/jiz058. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30726973

HIV risk behaviours among women who inject drugs in coastal Kenya: findings from secondary analysis of qualitative data. 

Mburu G, Limmer M, Holland P. 

Harm Reduct J. 2019;16(1):10. Published 2019 Feb 6. doi:10.1186/s12954-019-0281-y

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364406/

Medikamente zur HIV-Prophylaxe: DAK-Gesundheit übernimmt Kosten für PrEP

Die DAK-Gesundheit übernimmt als erste Krankenkasse die Kosten für die sogenannte HIV-Präexpositionsprophylaxe (PrEP). Dabei handelt es sich um Medikamente, die eine HIV-Infektion verhindern können. 
Die Arzneimittel werden zusammen mit anderen Arzneistoffen bereits seit Jahren genutzt, um bestehende HIV-Infektionen zu behandeln. Inzwischen sind sie auch zur Vorbeugung zugelassen, gehören jedoch nicht zu den regulären Leistungen der Krankenkassen. (DAK – Deutsche Angestellten Krankenkasse, 13.02.2019)

https://www.dak.de/dak/leistungen/hiv-prophylaxe-2037472.html

USA. Black Americans and HIV/AIDS: The Basics

Key Facts:

- Black Americans have been disproportionately affected by HIV/AIDS since the epidemic’s beginning, and that disparity has deepened over time. 

- Although they represent only 12% of the U.S. population, Blacks account for a much larger share of HIV diagnoses (43%), people estimated to be living with HIV disease (42%), and deaths among people with HIV (43%) than any other racial/ethnic group in the U.S. 

- Among Black Americans, Black women, youth, and gay and bisexual men have been especially hard hit. 

- A number of challenges contribute to the epidemic among Blacks, including poverty, lack of access to health care, higher rates of some sexually transmitted infections and smaller sexual networks, lack of awareness of HIV status, and stigma. 

- Despite this impact, recent data indicate some encouraging trends, including declining new HIV diagnoses among Blacks overall, especially among women, and a leveling off of new diagnoses among Black gay and bisexual men. However, given the epidemic’s continued and disproportionate impact among Blacks, a continued focus is critical to addressing HIV in the United States. (KFF – Kaiser Family Foundation, USA, 07.02.2019)

https://www.kff.org/hivaids/fact-sheet/black-americans-and-hivaids-the-basics

USA. The HIV/AIDS Epidemic in the United States: The Basics

Key Facts

The first cases of what would later become known as AIDS were reported in the United States in June of 1981. Today, there are more than 1.1 million people living with HIV and more than 700,000 people with AIDS have died since the beginning of the epidemic.

HIV continues to have a disproportionate impact on certain populations, particularly racial and ethnic minorities and gay and bisexual men and other men who have sex with men. 

HIV testing is important for both treatment and prevention efforts. Yet, 14% of those infected with HIV are unaware they are infected.

Antiretroviral therapy (ART) has substantially reduced AIDS-related morbidity and mortality and improved long-term outcomes for people with HIV. Treatment guidelines recommend initiating treatment as soon as one is diagnosed with HIV. According to the U.S. Centers for Disease Control and Prevention (CDC), when an individual living with HIV is on antiretroviral therapy and the level of HIV in their body is undetectable, there is “effectively no risk” of sexual transmission. Still, many people with HIV are not in care, on treatment, or have their virus under control.

(...) (Kaiser Family Foundation, USA, 04.02.2019)

https://www.kff.org/hivaids/fact-sheet/the-hivaids-epidemic-in-the-united-states-the-basics

Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention.

Cooke A, Saleem H, Hassan S, Mushi D, Mbwambo J, Lambdin B.

Addict Sci Clin Pract. 2019 Jan 28;14(1):3. doi: 10.1186/s13722-019-0133-9.

https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-019-0133-9

Performance indicator as the main and the only goal: a “dark side” of the intervention aims to accelerate HIV treatment entry among people who inject drugs in Kyiv, Ukraine

Alexandra Dmitrieva, Vladimir Stepanov, Ievgeniia-Galyna Lukash and Anna Martynyuk

Harm Reduction Journal2019, 16:8, doi.org/10.1186/s12954-019-0279-5

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0279-5

Kanada. CHIWOS - The Canadian HIV Women’s Sexual & Reproductive Health Cohort Study / L’étude sur la santé sexuelle et reproductive des femmes vivant avec le VIH (FVVIH) au Canada

CHIWOS is committed to creating new knowledge that will be used to support women living with HIV in Canada to achieve optimal health and well-being / CHIWOS est engagé dans une démarche visant à créer des nouvelles connaissances qui seront utilisées afin de soutenir les femmes vivant avec le VIH au Canada dans l’atteinte de leur niveau optimal de santé et de bien-être. (Stand Februar 2019)

https://www.chiwos.ca

Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence. 

Feyissa GT, Lockwood C, Woldie M, Munn Z (2019) 

PLoS ONE 14(1): e0211298. doi.org/10.1371/journal.pone.0211298

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211298

Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.

Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, van der Heijden Y, Wood R, Rustomjee R, Kana BD.

Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30477-8. doi: 10.1016/S1473-3099(18)30477-8. 

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30477-8/fulltext

Transmission of drug-resistant tuberculosis in HIV-endemic settings.

Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A.

Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30537-1. doi: 10.1016/S1473-3099(18)30537-1. 

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30537-1/fulltext

Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use

Walker, Shelley et al.

The Lancet Infectious Diseases , Volume 19 , Issue 2 , 130 - 131 

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30801-6/fulltext

Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Hemelaar, JorisAbimiku, Alash'le G et al.

The Lancet Infectious Diseases , Volume 19 , Issue 2 , 143 - 155 

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30647-9/fulltext

EACS-HIV-LEITLINIEN - Version 9.1 - Oktober 2018 – Englisch

EACS produces the European Guidelines for treatment of HIV-positive adults in Europe. The English version is regularly updated by the guideline panels. A major update is published once per year in autumn and translated into additional languages. (European AIDS Clinical Society / EACS)

http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf

HIV. Neue EACS Leitlinien 

Die Europäische Aids-Gesellschaft hat im Oktober die Leitlinien aktualisiert. Dabei folgt sie mehr denn je internationalen Trends. Hier die wichtigsten Neuerungen.(Die deutsche Übersetzung liegt noch nicht vor, Anm. Forum Substitutionspraxis) (hiv&more, Ausgabe 4/2018)

https://www.hivandmore.de/archiv/2018-4/HIV-m4_18_Akt_NeueEACSLeitlin.pdf

Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.

Hauser A, Hofmann A, Meixenberger K, Altmann B, Hanke K, Bremer V, et al. (2018) 

PLoS ONE 13(11): e0206234. doi.org/10.1371/journal.pone.0206234

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0206234

Influence of substance use and cognitive impairment on adherence to antiretroviral therapy in HIV+ patients.

Sánchez-Rivero I, Madoz-Gúrpide A, Parro-Torres C, Hernández-Huerta D, Ochoa Mangado E.

Adicciones. 2018 Nov 21;0(0):1025. doi: 10.20882/adicciones.1025. 

(-> Download this PDF file)

http://adicciones.es/index.php/adicciones/article/view/1025/993

Behavioral and Clinical Characteristics of American Indian/Alaska Native Adults in HIV Care - Medical Monitoring Project, United States, 2011-2015.

Baugher AR, Beer L, Bradley HM, Evans ME, Luo Q, Shouse RL.

MMWR Morb Mortal Wkly Rep. 2019 Jan 4;67(5152):1405-1409. doi: 10.15585/mmwr.mm675152a1.

https://www.cdc.gov/mmwr/volumes/67/wr/mm675152a1.htm

HIV knowledge and risk behaviors among drug users in three Vietnamese mountainous provinces.

Nguyen TMT, Tran BX, Fleming M, Pham MD, Nguyen LT, Nguyen ALT, Le HT, Nguyen TH, Hoang VH, Le XTT, Vuong QH, Ho MT, Dam VN, Vuong TT, Nguyen V, Nguyen HLT, Do HP, Doan PL, Nguyen HH, Latkin CA, Ho CSH, Ho RCM.

Subst Abuse Treat Prev Policy. 2019 Jan 15;14(1):3. doi: 10.1186/s13011-019-0191-8.

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-019-0191-8

Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.

Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156. 

Abstract -> open access -> pdf

https://pdfs.journals.lww.com/aidsonline/9000/00000/Trends_in_cause_specific_mortality_in.96993.pdf

Differences in the rate of nicotine metabolism among smokers with and without HIV.

Ashare RL, Thompson M, Leone F, Metzger D, Gross R, Mounzer K, Tyndale RF, Lerman C, Mahoney MC, Cinciripini P, George TP, Collman RG, Schnoll R.

AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002127. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30649060

Live Imaging of HIV-1 Transfer across T Cell Virological Synapse to Epithelial Cells that Promotes Stromal Macrophage Infection

Real, Fernando et al.

Cell Reports , Volume 23 , Issue 6 , 1794 - 1805 

https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30570-9

Einige Opioide erhöhen Pneumonierisiko

New Haven/Connecticut – Die Einnahme von Opioid-Schmerzmitteln erhöht das Risiko auf eine ambulant erworbene Pneumonie. Am meisten waren in einer Fall-Kontroll-Studie in JAMA Internal Medicine(2019; doi: 10.1001/jamainternmed.2018.6101) Patienten gefährdet, die aufgrund einer HIV-Infektion eine geschwächte Immunabwehr hatten und/oder mit Opioiden behandelt wurden, die eine immunsupprimierende Nebenwirkung haben. (aerzteblatt.de, 09.01.2019)

https://www.aerzteblatt.de/nachrichten/100244/Einige-Opioide-erhoehen-Pneumonierisiko